Calcium gluconate
Producer: JSC Borisovsky Plant of Medical Supplies Republic of Belarus
Code of automatic telephone exchange: A12AA03
Release form: Firm dosage forms. Tablets.
General characteristics. Structure:
Active ingredient: 500 mg of calcium of a gluconate in each tablet.
Excipients: potato starch, talc, calcium stearate, silicon dioxide colloid anhydrous.
Pharmacological properties:
Pharmacodynamics. Normalizes exchange of calcium in an organism.
Pharmacokinetics. In digestive tract about one third of poreblyaemy calcium is soaked up, it is preferential in a small intestine. In blood calcium is as free (ionized), and in a coherent form. About 20% of calcium are removed with urine, 80% - through intestines.
Indications to use:
The states which are followed by deficit of calcium. As an additional tool at therapy of osteoporosis, osteomalacy, rickets, after a gastreektomiya, malabsorption.
Route of administration and doses:
Appoint inside, before meal. Before a proglatyvaniye the tablet needs to be crushed or chewed. The adult appoint 2-6 tablets 2-3 times a day. To children 6 years – on 3 - 4 tablets 2-3 times a day are more senior.
The course of treatment is defined by the doctor and averages from 10 days to 1 month.
Features of use:
Patients should appoint drugs of calcium with care with heart diseases or a sarcoidosis. Careful control of amount of calcium in calcium excretion blood with urine at purpose of high doses of drug is necessary, especially at children. Treatment has to be suspended if calcium level in blood exceeds 2,625 – 2,75 mmol/l or if calcium excretion with urine exceeds 5 mg/kg. It is necessary to avoid high consumption of vitamin D during calcium therapy.
Or with a nephrolithiasis in the anamnesis appointment has to be carried out by the patient with an insignificant hypercalcuria, decrease in glomerular filtering with care and under control of content of calcium in urine. For decrease in risk of development of a nephrolithiasis plentiful drink is recommended.
Pregnancy and lactation. At the pregnant women accepting calcium drugs together with vitamin D the probability of development of a hypercalcemia increases. In the recommended doses administration of drugs of calcium does not cause any negative effects for a fruit, use is safe and when feeding by a breast.
Side effects:
Seldom soft gastrointestinal frustration: lock, diarrhea. Disturbances of a cordial rhythm and bradycardia are possible.
Interaction with other medicines:
Thiazide diuretics reduce calcium excretion with urine that increases risk of development of a hypercalcemia.
To the patients receiving cardiac glycosides, drugs of calcium are contraindicated.
Drugs of calcium can reduce absorption of drugs of a tetracycline row in a GIT, in this regard the interval between reception of these drugs has to be not less than 3 hours.
Contraindications:
Hypercalcemia, hypercoagulation, atherosclerosis, urolithiasis.
Overdose:
The intentional overdose is improbable. Symptoms: anorexia, slackness, nausea, vomiting, a headache, strong thirst, dizziness, increase in level of urea in blood. Calcium can be deposited in kidneys, walls of arteries.
Treatment: calcium consumption minimizing, cancellation of the drugs promoting a hypercalcemia (tiazida, vitamin D), correction of dehydration and an electrolytic imbalance, if necessary purpose of loopback diuretics (furosemide). In hard cases, a significant amount of calcium can be removed by peritoneal dialysis. Patients with symptoms of overdose have to avoid influence of direct sunshine. At overdose treatment by calcium special attention should be paid to patients with renal failures or a liver.
Storage conditions:
In the place protected from moisture, at a temperature not over 25 ºС. To store in the place, unavailable to children. A period of validity - 5 years. Not to use after the termination of a period of validity.
Issue conditions:
Without recipe
Packaging:
10 tablets in a blister strip packaging or in planimetric bezjyacheykovy packaging; on 1 or 5 planimetric strip or planimetric bezjyacheykovy packagings together with a leaf insert in a pack. For treatment and prevention facilities: on 300 planimetric cell or on 390 planimetric bezjyacheykovy packagings together with 10 instructions on a medical use in a box.